A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific ...

Prostate-specific antigen screening resulted in 13% lower prostate cancer mortality over a median 23 years of follow-up.

The European Randomized Study of Screening for Prostate Cancer (ERSPC) sheds new light on the long-term impact of ...

Observational data suggested that men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle. A higher prostate cancer behavior score was associated with reductions in ...

SCREENING men for prostate cancer could slash deaths by 13 per cent, saving thousands of lives a year, a study suggests. Results of the long-term European trial – one of the largest in ...

After 23 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirmed a 13% lower prostate cancer mortality with PSA testing and an improved harm–benefit ratio ...

Prostate cancer screening for over-50s would save thousands of lives, experts have claimed as the UK decides whether or not to introduce a programme on the NHS.

Investigators analyzed exfoliated cells in urine test specimens to identify 50 candidate RNAs for prostate cancer detection.

Men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle, despite no reduction in prostate cancer-specific mortality, according to a large observational study. A ...